Investigational drug · Phase 2
DA-020
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chemotherapy Induced Alopecia, Chemotherapy Side Effects.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "DA-020"
First trial start
2026
May 16, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DA-020", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chemotherapy Induced Alopecia
- Chemotherapy Side Effects
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "DA-020" as an intervention, largest first.
Applied Biology, Inc.Industry
NCT07397325 · 60 participants (planned) · Start May 16, 2026 · Primary completion Feb 5, 2027
Drug: DA-020; Placebo and 1 more · For: Chemotherapy Induced Alopecia; Chemotherapy Side Effects
Sites: Manaus, Brazil; Rome, Italy
- Pharmacokinetic Study of DA-020Withdrawn
Applied Biology, Inc.Industry
NCT07402330 · 0 participants · Start Apr 16, 2026 · Primary completion Oct 19, 2026
Drug: DA-020 (0.1%); DA-020 (0.2%) and 1 more · For: Chemotherapy Induced Alopecia; Chemotherapy Side Effects
Sites: Manaus, Brazil; Rome, Italy
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chemotherapy Induced Alopecia
- DA-007Phase 31 trial
Applied Biology, Inc. · Chemotherapy Induced Alopecia, Chemotherapy Side Effects
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.